We are live on ! Find out more
BIB icon

ProShares Ultra NASDAQ Biotechnology
BIB

31 hedge funds and large institutions have $19.8M invested in ProShares Ultra NASDAQ Biotechnology in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.88% more ownership

Funds ownership: 0% → 4.88% (+4.9%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less funds holding

Funds holding: 35 → 31 (-4)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

31% less capital invested

Capital invested by funds: $28.7M → $19.8M (-$8.93M)

32% less call options, than puts

Call options by funds: $6.49M | Put options by funds: $9.59M

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9

Holders
31
Holders Change
-4
Holders Change %
-11.43%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
4
Reduced
9
Closed
11
Calls
$6.49M
Puts
$9.59M
Net Calls
-$3.1M
Net Calls Change
-$3.22M

Top Buyers

1
VKH
Virtu KCG Holdings
New York
+$498K
2
Morgan Stanley
Morgan Stanley
New York
+$472K
3
HF
HRT Financial
New York
+$442K
4
SPC
Sigma Planning Corp
Michigan
+$416K
5
Wolverine Trading
Wolverine Trading
Illinois
+$294K

Top Sellers

1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.97M
2
TRCT
Tower Research Capital (TRC)
New York
-$1.22M
3
BG
Bellevue Group
Switzerland
-$1.07M
4
PCA
Private Capital Advisors
Connecticut
-$831K
5
TFA
Toth Financial Advisory
Virginia
-$790K
Name Holding Trade Value Shares
Change 		Change in
Stake
RIA
1
RPG Investment Advisory
California
$4.19M -$223K -5,217 -5%
OPPM
2
Opus Point Partners Management
New York
$3.39M – – –
CIC
3
Chase Investment Counsel
Virginia
$1.85M – – –
BA
4
BKS Advisors
Michigan
$1.48M -$458K -10,725 -22%
Creative Planning
5
Creative Planning
Kansas
$1.29M +$10.9K +256 +0.8%
TRCT
6
Tower Research Capital (TRC)
New York
$898K -$1.22M -28,667 -56%
TH
7
Timber Hill
Connecticut
$887K +$28.5K +667 +3%
BG
8
Bellevue Group
Switzerland
$818K -$1.07M -25,000 -55%
Morgan Stanley
9
Morgan Stanley
New York
$621K +$472K +11,047 +245%
VKH
10
Virtu KCG Holdings
New York
$466K +$498K +11,672 New
LPL Financial
11
LPL Financial
California
$441K -$82.5K -1,931 -15%
Jane Street
12
Jane Street
New York
$416K -$161K -3,766 -27%
HF
13
HRT Financial
New York
$413K +$442K +10,360 New
BRC
14
Bell Rock Capital
Delaware
$400K +$427K +10,000 New
SBIA
15
Sheaff Brock Investment Advisors
Indiana
$399K – – –
SPC
16
Sigma Planning Corp
Michigan
$389K +$416K +9,735 New
Wolverine Trading
17
Wolverine Trading
Illinois
$274K +$294K +6,874 New
Koshinski Asset Management
18
Koshinski Asset Management
Illinois
$272K -$16.5K -386 -5%
BPC
19
Banque Pictet & Cie
Switzerland
$239K +$256K +6,000 New
VF
20
Virtu Financial
New York
$213K +$228K +5,341 New
BGC
21
Blue Granite Capital
South Carolina
$120K +$128K +3,000 New
Simplex Trading
22
Simplex Trading
Illinois
$96K -$897 -21 -0.9%
CAL
23
Capital Analysts LLC
Pennsylvania
$69K – – –
WA
24
WFG Advisors
Texas
$59K – – –
Bank of America
25
Bank of America
North Carolina
$44K -$25.6K -600 -35%
1
2

BIB Hedge Fund Activity: Q4 2016 in Review

31 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2016, worth a combined $19.8M — down 31% from $28.7M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of BIB and 8 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 4 added.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $498K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.97M sold.

  • 31 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2016, down from 35 in Q3 2016.
  • Funds reported $19.8M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2016, down 31% quarter-over-quarter.
  • 8 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2016 and 11 closed out, a net change of -3 holders.
  • The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2016 was Virtu KCG Holdings, an estimated $498K added.
  • The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2016 was Susquehanna International Group, an estimated $1.97M sold.

Based on aggregated 13F filings for Q4 2016.